Replies to post #85494 on Biotech Values

[DewDiligence]

Re: Qnexa vs Contrave

Somehow nobody seems to be talking about the side effect profile of the OREX drug. Wellbutrin has a suicide black box, and the other constituent (naltrexone) is well known for making people feel out of sorts, perhaps because it blocks endorphins.

Moreover, Wellbutrin has its own seizure risk. From page 5 of the FDA label:

[Wellbutrin] may cause generalized seizures in a dose-dependent manner with an approximate incidence of 0.4% (4/1,000). This incidence of seizures may exceed that of other marketed antidepressants by as much as 4-fold.

[genisi]

On CNS side effects of VVUS drug, I've posted similar thoughts (http://siliconinvestor.advfn.com/readmsg.aspx?msgid=26052980). Safety profile looks approvable to me although the FDA will probably ask for a panel review as well as REMS program, especially since obesity drugs are expected to be overused. Other problems I see for VVUS are reimbursement (that goes for all obesity branded drugs), use of Qnexa's generic components, and possible IP issue with JNJ.